Michael Zering Email & Phone Number
Who is Michael Zering? Overview
A concise factual answer block for searchers comparing this professional profile.
Michael Zering is listed as CEO and Co-founder at Apricot Therapeutics AG | APRICOT BIO, based in Zurich, Switzerland. AeroLeads shows a matched LinkedIn profile for Michael Zering.
Michael Zering previously worked as Founder & CEO at Apricot Therapeutics Ag and Deloitte Switzerland at Deloitte. Michael Zering holds Oxford Banking Governance Program, Executive Program from Saïd Business School, University Of Oxford.
Email format at Apricot Therapeutics AG | APRICOT BIO
This section adds company-level context without repeating Michael Zering's masked contact details.
Review company-level records connected to Michael Zering before choosing the right outreach path.
About Michael Zering
During my 15-plus years of experience as a change, finance, risk, and compliance specialist–-five with a Big Four consulting firm–-I have provided solutions to the financial services industry during pivotal phases of the credit crisis, subsequent aggressive downsizing, and numerous restructurings. I bring an in-depth understanding of Tier-1 front-to-back Equities and FICC trading and accounting systems and have led typically complex projects, resolving issues through deep analysis within finance, risk, treasury, and legal functions to build transparency, clarity, operational optimization, risk reduction, and design of regulatory-driven transformation. I am a native speaker of English with conversational German (B2)
Michael Zering's current company
Company context helps verify the profile and gives searchers a useful next step.
Michael Zering work experience
A career timeline built from the work history available for this profile.
Founder & Ceo
CurrentThe BIG goal in biology is understanding genotype in a way that predicts phenotype. Imagine being a doctor and having access to a 'Google Maps' of your patient's biopsy, allowing you to simultaneously navigate multiple layers of crucial information, at different scales, about how the cells in your biopsy respond to various drugs. Being able to predict the complex responses of individual cells to drugs using our proprietary 4i technology will revolutionize clinical decision making. Apricot Therapeutics AG is a spin-off from ETH and University of Zürich commercializing 17 years of image-based systems biology. Our mission: trail-blaze precision medicine for patient care (hospitals/clinics) + drug discovery (Pharma)www.Apricotx.com
Deloitte Switzerland
★ Supported legal & compliance initiative for a securities contract due diligence project across 50+ jurisdictions as part of pre parent bank merger of 2 banks★ Called in to support Client Risk Scoring impacted by outstanding FINMA observations. Client risk model sensitivity, simulations, rescoring post model change and story-lining to influence pending decisions whether to stop or continue investment★ Driving a simplification initiative—one of the top 10 strategic initiatives within the Wealth Management group—across eight domains in the Americas, creating governance structure and communications. I set the stage for success by securing buy-in from the domain leads for the project. ★ Facilitated operational readiness testing for pending release of new wealth management platform across 22 Risk monitoring systems (AML, credit ratio + transaction breaches, client suitability, KYC) ensuring accuracy at all levels and laying groundwork for successful deployment.★ Driving Credit Risk Officer (CRO) requirements for an Impairment Project for US GAAP. Facilitation across CFO, CRO, CRM groups. I tracked business readiness for go-live, drafted qualitative disclosure narratives for the 1Q20 external report, and tracked monthly CECL provisions.★ Supported formation of critical new compliance area through establishment of Chief Data Officer team tasked with implanting new DQ control / surveillance strategy. Governance adoption + control enhancements for: AML transaction monitoring, Sanctions screening, Client Risk Mgmt, RM surveillance, strategic vs non-core systems assessment
Independent Consultant
★ Supported two large, multifaceted global change projects under contract, providing business analysis to address credit, market, liquidity and operational risk. ★ Oversaw delivery of Single Client Identifier Program with 7M CHF budget that aggregated exposure to a single client name to enhance monitoring for tax evasion, ACB, AML and KYC data quality★ Impairment Program (CHF 15m budget) for the Credit Risk Officer that changed accounting for credit losses on accrual accounting loans and commitments to bring the bank into compliance with Financial Accounting Board standards (International Financial Reporting Standard 9) and improve the bank’s risk management.
Senior Manager, Strategy & Operations
As Senior Manager★ Supported the Project Management Office on global regulatory implementation of the Basel Committee on Banking Supervision and International Organization of Securities margin rules program for new collateral requirements for non-centrally cleared Over-the-Counter (OTC) derivatives to reduce or mitigate risk. ★ On behalf of Group Counsel (client-side), led Legal Stream to ensure that trading hubs in Europe and Middle East and Asia and Pacific regions were ready to comply with appropriate legal documentation (e.g. insurance and investment products) and collateral infrastructure supporting non-centrally cleared OTC trading for in-scope counterparties. Framework impacted AML and KYC monitoring★ Served as part of the management team for the strategy and operations practice focused on implementing new regulatory initiatives affecting the Swiss financial services industry on a global scale. I managed restructuring initiatives–on-shore, near-shore, off-shoring (ONO) projects–on behalf of a major bank; advised clients on strategy development, cost allocation management, and cost reduction; and recruited and mentored new talent.
Director, Accounting And Controlling Group (Gac)
In this position I served as a Member of the Chief of Staff team supporting the Head of the Accounting and Controlling Group (GAC). I helped ensure the smooth operation of the department and implementation of business-wide action plans and key initiatives. I also managed monthly business planning and financial forecasting in line with our one-year strategy, with a focus on cost control and risk awareness and mitigation. More specifically, I:★ Facilitated access to timely and accurate information to allow business divisions to evaluate and challenge their allocations at the functional level. ★ Drove a cost allocation pilot that provided greater transparency to business divisions as well as significant improvement of the cost view from a business division level down to the performance layer view. ★ Managed group-wide the quarterly and annual process for Sarbanes-Oxley Act Section 302, coordinating with top bank management across all functions and ensuring compliant disclosure procedures and controls. ★ Supported two-year ONO project across GAC that achieved savings of $3B CHf through relocation of hundreds of positions from Switzerland to lower cost locations> Managed to accomplish this while maintaining uninterrupted business operations, alignment with our compliance policy, and effective knowledge transfer.
Director, Group Treasury, Funding
In this position, I reviewed and redesigned the processes and tools for governance and surveillance during a turbulent period at UBS in the wake of global financial crisis. This involved managing relations with regulators, undertaking a deep analysis of the implications of new regulatory policies, and developing comprehensive solutions to comply with new requirements.In addition, I provided ongoing Group-level funding governance and oversight, monitored funding efficiency and diversification, and provided framework and support for cost-effective funding of operating business.
Fx Derivatives, Business Unit Control
Business unit controlling, Accounting and controlling
Equities Business Unit Control
Business unit controlling, Equities, Accounting and controlling
Partner / Business Development
Senior Level Consulting Services Provider, Outsourced projects, IT Audits, Datawarehousing, Business Intelligence, Data Integration, particular focus on the Financial Services / Investment Banking sectors, Food & Agriculture, Pharma & Biotech
Business Development
Recruitment, Head Hunter, Financial Services Industry
Business Development
Recruitment, Financial Services Industry
Michael Zering education
Oxford Banking Governance Program, Executive Program
B.A., Economics, Sociology
Frequently asked questions about Michael Zering
Quick answers generated from the profile data available on this page.
What company does Michael Zering work for?
Michael Zering works for Apricot Therapeutics AG | APRICOT BIO.
What is Michael Zering's role at Apricot Therapeutics AG | APRICOT BIO?
Michael Zering is listed as CEO and Co-founder at Apricot Therapeutics AG | APRICOT BIO.
Where is Michael Zering based?
Michael Zering is based in Zurich, Switzerland while working with Apricot Therapeutics AG | APRICOT BIO.
What companies has Michael Zering worked for?
Michael Zering has worked for Apricot Therapeutics Ag | Apricot Bio, Apricot Therapeutics Ag, Deloitte, Credit Suisse, and Deloitte Consulting Ag.
How can I contact Michael Zering?
You can use AeroLeads to view verified contact signals for Michael Zering at Apricot Therapeutics AG | APRICOT BIO, including work email, phone, and LinkedIn data when available.
What schools did Michael Zering attend?
Michael Zering holds Oxford Banking Governance Program, Executive Program from Saïd Business School, University Of Oxford.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial